Cara Therapeutics (Cara Therapeutics) Cash-to-Debt : 16.55 (As of Dec. 2023)

View and export this data going back to 2014. Start your Free Trial

What is Cara Therapeutics Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Cara Therapeutics's cash to debt ratio for the quarter that ended in Dec. 2023 was 16.55.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, Cara Therapeutics could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for Cara Therapeutics's Cash-to-Debt or its related term are showing as below:

CARA' s Cash-to-Debt Range Over the Past 10 Years
Min: 16.55 Med: 5037.9 Max: No Debt
Current: 16.55

During the past 13 years, Cara Therapeutics's highest Cash to Debt Ratio was No Debt. The lowest was 16.55. And the median was 5037.90.

CARA's Cash-to-Debt is ranked better than
62.7% of 1539 companies
in the Biotechnology industry
Industry Median: 6.5 vs CARA: 16.55

Cara Therapeutics Cash-to-Debt Historical Data

The historical data trend for Cara Therapeutics's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Cara Therapeutics Cash-to-Debt Chart

Cara Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

35.89

34.30

45.48

75.81

16.55

Cara Therapeutics Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															75.81	78.49	96.43	10.74	16.55

Competitive Comparison of Cara Therapeutics's Cash-to-Debt

For the Biotechnology subindustry, Cara Therapeutics's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cara Therapeutics's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cara Therapeutics's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Cara Therapeutics's Cash-to-Debt falls into.

Cara Therapeutics Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Cara Therapeutics's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	100.758	/	(0	+	6.088)
	=	16.55

Cara Therapeutics's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	100.758	/	(0	+	6.088)
	=	16.55

Cara Therapeutics (NAS:CARA) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Cara Therapeutics Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Cara Therapeutics's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Cara Therapeutics (Cara Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cara Therapeutics Inc (NAS:CARA) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

69C:Germany 69C:Germany

Address

107 Elm Street, 9th Floor, 4 Stamford Plaza, Stamford, CT, USA, 06902

Website

https://www.caratherapeutics.com

Cara Therapeutics Inc is an emerging biotechnology company involved in the development of novel therapeutics to treat human diseases associated with inflammation, pain, and pruritus. Cara's most advanced compound, CR845, aims to treat acute pain and pruritus. This patented compound has analgesic, anti-inflammatory, and antipruritic properties that can be used for multiple therapeutic applications. Additionally, Cara's objective is to use its proprietary drug-screening technology to develop a future pipeline of first-in-class molecules with analgesic and anti-inflammatory features.

Executives

Christopher Posner	director	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Helen M Boudreau	director	200 TECHNOLOGY SQUARE, 4TH FLOOR, CAMBRIDGE MA 02139
Joana Goncalves	officer: Chief Medical Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Scott Terrillion	officer: Sec'y; Chief Compliance & G.C.	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, 9TH FL, STAMFORD CT 06902
Menzaghi Frederique Ph.d.	officer: VP-Research & Development	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Moltke Lisa Von	director	C/O SERESTHERAPEUTICS, INC., 200 SIDNEY STREET, CAMBRIDGE MA 02139
Martin Vogelbaum	director	675 ALMANOR AVE, SUNNYVALE CA 94085
Ryan D Maynard	officer: Chief Financial Officer	RIGEL PHARMACEUTICALS, INC., 1180 VETERANS BLVD., SOUTH SAN FRANCISCO CA 94080
Csl Ltd	10 percent owner
Jeffrey L. Ives	director	C/O CARA THERAPEUTICS, INC., 1 PARROTT DRIVE, SHELTON CT 06484
Bains Harrison M Jr	director
Thomas Charles Reilly	officer: Chief Financial Officer	C/O CARA THERAPEUTICS, INC., 4 STAMFORD PLAZA, 107 ELM STREET, STAMFORD CT 06902
Vifor Fresenius Medical Care Renal Pharma Ltd.	10 percent owner	RECHENSTRASSE 37, CH-9014, ST. GALLEN V8 9014
Vifor (international) Ltd	10 percent owner	RECHENSTRASSE 37, ST. GALLEN V8 9000
Vifor Pharma Ltd.	10 percent owner	UNTERMATTWEG 8, BERNE V8 CH-3027